Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of mRNA-1018-H5 Pandemic Influenza Vaccine in Adults ≥18 Years of Age

NCT07496450 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT07496450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07496450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of mRNA-1018-H5 Pandemic Influenza Vaccine in Adults ≥18 Years of Age
Lead sponsor
ModernaTX, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 23, 2026
Completion date
January 28, 2027
Enrollment
4,050 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

influenza